Key result
Aspirin-free dual therapy linked to ~2-minute shorter bleeding time versus triple therapy in AF post-PCI.
Why the study?
Does dual antithrombotic therapy without aspirin improve hemostasis compared to triple antithrombotic therapy in patients with atrial fibrillation undergoing PCI?
Cohort (n=34)
Does dual antithrombotic therapy without aspirin improve hemostasis compared to triple antithrombotic therapy in patients with atrial fibrillation undergoing PCI?
Answers are grounded in this paper and cite their sources.
Dual antithrombotic therapy with a potent P2Y12 inhibitor and DOAC improves hemostasis by sparing COX-1-mediated platelet activation while maintaining comparable effects on other pathways compared to triple therapy.
Dual antithrombotic therapy (DAT) without aspirin reduces bleeding compared with triple antithrombotic therapy (TAT) in patients with atrial fibrillation who have undergone percutaneous coronary intervention, without apparently increasing ischemic events. A prospective pharmacodynamic study was performed to investigate the impact of aspirin on bleeding time, platelet function and fibrin clot analysis in this population. Patients receiving TAT (n = 16), comprising aspirin, ticagrelor/prasugrel and a direct-acting oral anticoagulant (DOAC), were compared with those receiving DAT without aspirin (n = 18). Bleeding time was reduced with DAT compared with TAT (median 27.8 vs 30.0 minutes, p = .005). Assessed by light transmission aggregometry, median platelet aggregation was significantly increased with DAT compared with TAT in response to arachidonic acid (63 vs 3%, p = .002) and collagen (72 vs 37%, p < .001) but not 5-μmol/L adenosine diphosphate (25 vs 27%, p = .966) or thrombin-receptor-activating peptide (37 vs 24%, p = .086). VerifyNow P2Y12 assay showed > 70% inhibition in all patients. Fibrin clot lysis time and maximum turbidity were similar between groups. Using P2Y12 inhibitors of consistent potency, DAT improves hemostasis through sparing cyclooxygenase-1-mediated platelet activation but has a comparable effect to TAT on other pathways and fibrin clot properties. DAT with ticagrelor/prasugrel and DOAC may provide sufficient antithrombotic effect without excessive anti-hemostatic effect.
No takes yet. Share an insight, caveat, or question.
Sammut et al. (2025) conducted a cohort in Atrial fibrillation post-percutaneous coronary intervention (n=34). Dual antithrombotic therapy (DAT) without aspirin vs. Triple antithrombotic therapy (TAT) including aspirin was evaluated on Bleeding time (minutes) (p=.005). Dual antithrombotic therapy without aspirin reduced bleeding time compared with triple therapy in patients with atrial fibrillation post-PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: